Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s Lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal Phase II study. ASH 2022;Abstract 610.
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial – ELEVATE RR. J Clin Oncol 2021;39(31):3441-52. Abstract
Carlo-Stella C et al. RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study. ASH 2022;Abstract 161.
Cohen YC et al. First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM). ASCO 2023;Abstract 8002.
Dhakal B et al. First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. ASCO 2023;Abstract LBA106.
Dreyling M et al. Triangle: Autologous transplantation after a rituximab/ibrutinib/ara-c containing induction in generalized mantel cell lymphoma – A randomized European MCL Network trial. ASH 2022;Abstract 1.
Eichhorst B et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med 2023;388(19):1739-54. Abstract
Frustaci AM et al. Results of MOLTO, a multicenter, open label, phase II clinical trial evaluating venetoclax, atezolizumab and obinutuzumab combination in Richter syndrome. ASCO 2023;Abstract 7502.
Gasparetto C et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Brit J Cancer 2022;126(5):718-25. Abstract
Goldschmidt H et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone in induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol 2022;9(11):e810-21. Abstract
Grosicki S et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): A randomised, open-label, phase 3 trial. Lancet 2020;396(10262):1563-73. Abstract
Gouill SL et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantel cell lymphoma: A phase 1/2 trial. Blood 2021;137(7):877-87. Abstract
Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage classic Hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.
Hillmen P et al. Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial. J Clin Oncol 2023;41(5):1035-45. Abstract
Kalakonda N et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): A single-arm, multinational, multicentre-open-label, phase 2 trial. Lancet Haematol 2020;7:e511-22. Abstract
Kambhampati S et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment. ASCO 2023;Abstract 7507.
Kaufman JL et al. An updated safety and efficacy analysis of venetoclax plus daratumumab and dexamethasone in an expansion cohort of a phase 1/2 study of patients with t(11;14) relapsed/refractory multiple myeloma. ASH 2022;Abstract 3232.
Kim TM et al. Odronextamab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) grade 1-3a: Results from a prespecified analysis of the phase 2 study ELM-2. ASH 2022;Abstract 949.
Kim W-S et al. Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from a prespecified analysis of the phase 2 study ELM-2. ASH 2022;Abstract 444.
Krishnan A et al. Cevostamab is efficacious and well tolerated in patients aged <65 and ≥65 years with relapsed/refractory multiple myeloma. International Myeloma Society Annual Meeting 2022;Abstract P-012.
Kumar SK et al. Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligibel patients with newly diagnosed multiple myeloma (NDMM): Updated analysis of the phase 3 MAIA study. ASH 2022;Abstract 4559.
Kumar SK et al. Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. ASH 2021;Abstract 84.
Lee HC et al. LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma. ASCO 2023;Abstract 8006.
Martin T et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from the IKEMA, a randomized phase 3 study. Blood Can J 2023;13(1):72. Abstract
Mato AR et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from the phase 1/2 BRUIN study. ASH 2022;Abstract 961.
Merryman R et al. Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status. ASCO 2023;Abstract 7506.
Nooka AK et al. Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies. ASCO 2023;Abstract 8008.
Nooka AJ et al. Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma patients (pts): A phase 2 study with safety run-in. ASCO 2023;Abstract 8001.
Richardson PG et al. Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial. ASCO 2022;Abstract LBA4.
Richardson PG et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med 2022;387(2):132-47. Abstract
Rodriguez-Otero P et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 2023;388(11):1002-14. Abstract
Seymour JF et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 2022;140(8):839-50. Abstract
Sharman JP et al. Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN. ASCO 2022;Abstract 7539.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Topp MS et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma (DLBC): Results from a phase Ib study. ASH 2022;Abstract 737.
Wang ML et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantel cell lymphoma: Additional patients and extended follow-up from the phase 1/2 BRUIN study. ASH 2022;Abstract 4218.
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantel-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract
Wang M et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantel cell lymphoma: The safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol 2021;14(1):179. Abstract
Weisel K et al. A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM‑3. ASCO 2023;Abstract 8007.
Westin J et al. Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma. ASCO 2023;Abstract LBA107.
Wierda WG et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in Richter transformation: Results from the phase 1/2 BRUIN study. ASH 2022;Abstract 347.